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Abstract 
Formalin-fixed paraffin-embedded (FFPE) archival clinical specimens are invaluable 
in discovery of prognostic and therapeutic targets for diseases such as cancer.  
However, the suitability of FFPE-derived genetic material for array-based 
comparative genomic hybridisation (array-CGH) studies is under-explored.  In this 
study, genetic profiles of matched FFPE and fresh-frozen specimens were examined 
to investigate DNA integrity differences between these sample types and determine 
the impact this may have on genetic profiles.  Genomic DNA was extracted from 
three patient-matched FFPE and fresh-frozen clinical tissue samples. T47D breast 
cancer control cells were also grown in culture and processed to yield a fresh T47D 
sample, a fresh-frozen T47D sample and a FFPE T47D sample. DNA was extracted 
from all samples, array-CGH conducted and genetic profiles of matched samples were 
then compared. A loss of high-molecular weight DNA was observed in the FFPE 
clinical tissues and FFPE T47D samples, respectively. A dramatic increase in absolute 
numbers of genetic alterations was observed in all FFPE tissues relative to matched 
fresh-frozen counterparts. In future, alternative fixation and tissue processing 
procedures, and/or new DNA extraction and CGH profiling protocols, may be 
implemented, enabling identification of changes involved in disease progression 
through the use of stored clinical specimens. 
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Introduction 
Genomic instability is a hallmark of human cancer [1].  Amplification or deletion of 
distinct sub-chromosomal areas can lead to over- or under-expression of key genes, 
thus conferring a growth advantage to malignant cells [2]. Conversely, deletions of 
tumour suppressor genes, such as those involved in cell death, may also push the 
genetic balance toward malignant growth.  Amplified genes are therefore important 
targets for therapeutic invention, and identification of such copy number alterations 
can help elucidate potential mechanisms involved in tumour development and 
progression, and identify cancer subtypes. 
The most widely used and successful technique to study copy number alterations 
(CNAs) is comparative genomic hybridisation (CGH).  Array-CGH is conducted by 
differentially labelling total genomic DNA from test and reference samples, followed 
by co-hybridisation onto an array consisting of DNA probes spanning the genome. 
The ratio of fluorescent intensities, allows identification of copy number change 
between test and reference samples. Classically, this technique has been successfully 
used on DNA extracted from fresh-frozen clinical tissue specimens, as these yield 
higher quality nucleic acids [3-5]. However, as the availability of fresh-frozen tissue 
is often limited, studies of archival formalin-fixed paraffin-embedded (FFPE) clinical 
tissue specimens with accompanying retrospective data would be of enormous benefit 
in elucidating key genes involved in disease progression. Array-CGH studies using 
FFPE DNA have been reported [6-8], although little is known of the true impact of 
tissue fixation and processing on resulting genetic profiles.   
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The present study was primarily performed to assess the correlation of array-CGH 
profiles of DNA extracted from matched FFPE and fresh-frozen tissues, investigate 
the number of CNAs present in DNA extracted from FFPE tissues with respect to 
their matched fresh-frozen counterparts, and to assess any difference in DNA quality 
between these sample types.   
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Materials and Methods 
Cell Line and Tissue Preparation 
T47D breast cells (E.C.A.C.C., UK) were cultured in DMEM + 10% FBS, 200mM L-
glutamine.  Three tissue culture flasks were grown to confluency.  Three identical cell 
T47D cell pellets were prepared and genomic DNA was immediately extracted from 
the first. A FFPE cell sample was prepared from the second pellet, by first fixing 
T47D cells by suspension in 10% neutral buffered formalin (NBF) for 1 hr at room 
temperature.  The pellet was centrifuged, formalin removed, 70% ethanol added, 
mixed and left overnight. The pellet was then dehydrated through increasing 
concentrations of ethanol (70%, 95%, 100%, 100%) at room temperature for 1hr 45m 
each and then finally in xylene at room temperature for two steps of 1hr 45m each. 
Liquid paraffin was added to the pellet and cells were maintained at 60°C (melting 
point of paraffin) and replaced every 20m for a period of 2hr to ensure removal of 
residual xylene. The pellet was then allowed to solidify a room temperature in fresh 
paraffin and was then implanted in a new paraffin block from which sections were 
then cut for DNA extraction from FFPE cells.  Fresh-frozen T47D cells were prepared 
by snap-freezing the third pellet of T47D cells in optimum cutting temperature 
(O.C.T.) matrix. The frozen block was stored at -80°C for one week, then trimmed to 
remove excess O.C.T matrix from the frozen cell pellet, and fresh-frozen DNA was 
extracted. 
Three cases of patient-matched fresh-frozen and FFPE colon cancer tissue samples 
were also acquired for array-CGH investigation from the Department of 
Histopathology, Beaumont Hospital, Dublin 9.  DNA was extracted from a 20µm 
section of each fresh-frozen tissue and each matched FFPE tissue, which had been 
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processed as follows. Colon cancer tissues for frozen storage were immediately frozen 
using liquid nitrogen upon reaching the histopathology laboratory from surgery.  
Samples were stored at -80°C for a maximum of 2 months prior to frozen sectioning 
on a cryostat. DNA was immediately extracted after sectioning.  Matched colon 
cancer FFPE tissues were fixed in 10% formalin for an average of 16 hr before 
embedding in paraffin.  Blocks were stored at room temperature for a maximum of 2 
months prior to sectioning.  DNA was then extracted within one week of sectioning.   
DNA Extractions 
DNA from all above sources was extracted using the NucleoSpin Tissue Kit 
(Clontech, USA). The following additional protocol was applied prior to DNA 
extraction from FFPE tissue. FFPE tissue sections were placed in 1.5ml tubes.  
Xylene (1ml) was added and mixed at room temperature for 30 min. Tubes were 
microcentrifuged for 3 min at 11,000 x g to pellet tissue, and subsequent supernatant 
removed.  Ethanol (96% v/v; 1ml) was added to each tissue, mixed, and 
microcentrifuged for 3 min at 11,000 x g then ethanol was removed. This step was 
repeated, and after removal of ethanol the tissue was incubated at 37°C until all 
ethanol had evaporated. The standard NucleoSpin Tissue Kit manual procedure was 
then applied to all tissues for extraction of DNA.  Extracted DNA was quantified 
using a NanoDrop ND-1000 Spectrophotometer (Nanodrop Technologies, USA).  
DNA integrity was assessed by analysis of 100ng DNA via 2% agarose gel 
electrophoresis. 
Array-CGH 
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The GenoSensor array-CGH platform (Vysis - Abbott Laboratories, USA) was 
utilised in this study.  In brief, test and reference DNA (100ng) were labelled with 
Cy3 and Cy5 fluorophores (1mM) respectively.  Labelled targets were DNase-treated 
for 1 hr at 15°C then purified by sodium acetate and ethanol precipitation steps. The 
quality of purified, labelled DNA was assessed by agarose gel electrophoresis.  Equal 
concentrations of labelled test and reference DNA were then combined and loaded 
onto the GenoSensor Array 300 array. Hybridisation was conducted in the presence of 
humidified 2X standard saline citrate (SSC)/50%(v/v) formamide for 60 hr at 37°C. 
Arrays were washed in 2X SSC/50%(v/v)  formamide, followed by 1XSSC. Spots 
were counterstained with DAPI and scanning was performed using the GenoSensor 
Reader System. 
Image Acquisition and Data Analysis 
The GenoSensor reader was used to acquire a three-color image of each microarray 
using a CCD camera and a 175W xenon light source. Automated analysis was then 
conducted by the GenoSensor Reader software as follows. Spot segmentation and 
identification was conducted to isolate and relate every DNA spot on the microarray 
to a particular DNA target clone. Spot intensity and brightness was measured for each 
spot and ratios of Cy3 to Cy5 fluorescence were calculated.  Ratio values were then 
normalized, subjected to statistical analysis using an analog of the t-test, and placed in 
a report format. This t-test analog takes account of modal target variability, replicate spot 
ratio variability of the target being assessed, and assumes a normal distribution of modal 
target mean ratios, thus providing an unbiased significance estimate for non-modality.  
The resulting target report contained the mean and coefficient-of-variation of the 
normalized CGH ratios of the three replicate spots, together with a significance or p-
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value that the mean ratio corresponds to a gain or loss of copy number for each target 
clone on the array. Only those targets whose computed p-values were less than 0.01 
for all samples were selected in this study. This was conducted to improve the 
stringency of results and, thus, the comparability of resulting genetic profiles of 
alternative sample types. Subsequent target report tables from matched fresh-frozen 
and FFPE specimens were compared and numbers of genetic alterations and areas of 
genomic change were recorded.  Additionally quality parameters, as set by the array 
manufacturers, were recorded for each array. Only those arrays passing all quality 
parameters were included in this study. 
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Results 
This study was conducted to primarily investigate the possible impact of formalin-
fixation and paraffin-embedding on DNA degradation and subsequent DNA profiling. 
Prior to profiling using array-CGH, we assessed possible differences in integrity of 
DNA extracted from FFPE and fresh-frozen matched samples by agarose gel 
electrophoresis using equal amounts of DNA.  Genomic DNA extracted from matched 
FFPE and fresh-frozen clinical samples show dramatic differences in quality by 
agarose gel electrophoresis (Figure 1).  Lanes 1-3 show a complete lack of high 
molecular weight DNA in FFPE clinical samples. Lanes 4-6 show the retention of 
high molecular weight DNA in fresh-frozen clinical samples, with minor degradation 
as indicated by the appearance of lower molecular weight DNA. DNA samples 
extracted from three alternatively-processed T47D breast cancer cell samples were 
also compared. Lane 8 shows the retention of high molecular weight DNA in the 
DNA extracted from fresh T47D cells. Lane 9 shows that snap-frozen O.C.T.-
embedded T47D cells produced DNA of high molecular weight with little 
degradation.  Lane 7 shows a large DNA smear, with the loss of the majority of high 
molecular weight DNA. This DNA, which was extracted from FFPE T47D cells, 
displayed the highest degradation of the three matched T47D samples. These results 
indicate that formalin-fixation and paraffin-embedding may have a negative effect on 
the quality of extracted DNA.   DNA yields from differentially-processed pellets of 
3.5 X 107 T47D cells also differed significantly.  Yields of 43.2, 7, and 1.6ug were 
quantified for fresh, OCT fresh-frozen, 1hr formalin-fixed cells, respectively. 
 
We next sought to identify any differences in the array-CGH profiles of DNA from 
alternatively-processed samples (Figure 2).  A dramatic difference in the total number 
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of statistically-relevant genetic changes between matched FFPE and fresh-frozen 
samples was observed (Figure 2a). Of the additional genetic changes observed in all 
FFPE specimens relative to matched counterparts, there was an almost equal increase 
amplifications and deletions (Figure 2b). No pattern of alterations or chromosomal 
region bias was evident in these FFPE tissues, as alterations occurred on almost all 
chromosomes.  Notably, an increase in the number of genetic alterations, from 28 to 
122, was observed for fresh- and FFPE-derived DNA from identical T47D breast 
tumour cell line samples. The absolute numbers of genetic changes, as well as regions 
where these occurred, in the fresh T47D DNA sample correlated well with those 
previously reported in the literature using standard chromosome CGH spreads and 
spectral karyotyping (SKY) techniques [9,10].   
 
Differences can also be observed when comparing array-CGH profiles of DNA 
extracted from the three alternatively fixed and processed T47D cell line-derived 
samples (Figure 3a).  Profiles of fresh and snap-frozen samples are almost identical; 
however, a large increase in genetic changes can be seen in the FFPE DNA sample.  
We also sought to examine the difference in array-CGH profiles of alternatively 
processed clinical samples. It can be seen that the array-CGH profiles of all three 
FFPE clinical samples display an obvious increase in genetic changes relative to their 
patient-matched fresh counterparts (Figure 3b).  
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Discussion 
We have shown that suitable quantities of DNA for investigation using the 
GenoSensor array-CGH platform can be obtained from both snap-frozen and FFPE 
samples.  Prior to conducting array-CGH, test genomic DNA was visualised by 
agarose gel electrophoresis to assess potential degradation.  As expected from 
previously published studies [11-14], all FFPE samples showed an increase in 
degradation, and a loss of high molecular weight DNA in comparison to matched 
fresh-frozen specimens.    A complete loss of high molecular weight DNA was 
observed in all FFPE clinical tissues examined, indicating a substantial deleterious 
effect of formalin fixation on DNA quality.  In our hands, different DNA extraction 
kits had negligible effects on DNA quality after formalin fixation, producing similar 
highly degraded DNA (data not shown). Formalin fixation alone was shown to be 
sufficient to produce degraded DNA, which showed multiple spurious genetic 
alterations in array-CGH profiles (Supplementary Figures 1 and 2). Additionally 
array-CGH genetic profiles of clinical archival FFPE and fresh-frozen colon tissues 
showed a notable increase in total numbers of statistically relevant genetic alterations 
in FFPE tissues compared to patient-matched fresh-frozen specimens.  
Previous reports have noted differences in DNA extracted from matched FFPE and 
fresh tissue specimens.  Inoue et al. and Serth et al. both reported a reduction in the 
yield of total genomic DNA from FFPE specimens compared to matched frozen 
counterparts [12,14].  Discordances between array-CGH profiles of alternatively 
processed samples have also been reported, noting the appearance of spurious copy 
number gains and losses in FFPE material only. Lee et al. noted that matched FFPE 
and frozen samples exhibited similar array-CGH profiles, but also observed several 
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discordant aberrations in FFPE samples [15].  Little et al. reported the same 
phenomenon, citing tumour heterogeneity, alternate tissue sampling, or a drop in 
reliability of DNA extracted from FFPE tissue as possible reasons for the aberrations 
[16].  Ghazani et al. showed aberrant changes in array-CGH profiles of cultured cells 
fixed for 30min, 20hr and 1 week [11]. It was concluded that samples fixed for 20 hr 
showed similar, but notably not identical, profiles to freshly harvested DNA.  
Although the above reports cited discordance between array-CGH profiles of FFPE 
and fresh-frozen tissue, the issue of false positive target discovery was not mentioned, 
nor were alternative tissue fixation or embedding processes suggested.  
Tissue processing by formalin-fixation followed by paraffin embedding provides an 
opportunity to store large banks of tissue and allows retrospective genomic studies of 
tumours to be performed, in which chromosomal imbalances associated with tumour 
development and progression may be identified.  In contrast, the creation and hosting 
of biobanks of fresh-frozen tissue comes with limitations such as storage space and 
power requirements.  
Currently in the clinical setting, emphasis is based on preservation of tissue 
morphology for pathological diagnosis, rather than the preservation of nucleic acids 
within tissue specimens.  10% buffered formalin, an aqueous dilution of 
formaldehyde, is the most widely used fixative as it preserves a wide range of tissues 
and tissue components and is inexpensive [17,18] .  However, formaldehyde is known 
to interact with DNA, and initiate DNA degradation [19].  Numerous additional 
factors can also influence the recovery of high-quality DNA from tissues.  Longer 
prefixation times, or time from surgery to fixation, can have detrimental effects on 
DNA integrity [20].  Although it has been reported that limited tissue fixation times 
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have minimal impact on array-CGH profiles [11], in the hospital laboratory, standard 
operating procedures can vary between hospitals and routine fixation times can vary 
from 6-48 hr.   
Numerous alternative fixatives to NBF have, however, been reported to have minimal 
impact of nucleic acids while maintaining tissue morphology for diagnosis [21-27].  
Alcohols such as ethanol and methanol have been shown to preserve high-quality 
RNA and DNA. However, alcohols are often not sufficient to maintain morphology 
for diagnosis (21, 25, 26).  The AMeX method, which is based on cold acetone 
fixation followed by clearing with  methyl benzoate and xylene, then embedding in 
paraffin, has been shown to be a versatile multipurpose tissue-processing procedure, 
maintaining tissue morphology and DNA integrity (23).  This method does, however, 
require longer fixation at colder temperatures than formalin fixation, but could be 
easily implemented in the clinical setting. 
The HOPE-technique (Hepes-Glutamic acid buffer mediated Organic solvent 
Protection Effect) utilises a protection solution comprised of the organic buffer 
acetone, as the only dehydrating agent, and pure paraffin of 52-54 °C melting 
temperature. HOPE-fixed sections have been shown to exhibit formalin-like 
morphology (22) and provide an excellent preservation of proteins and nucleic acids 
(DNA and RNA) (28).  High-quality DNA and RNA have been extracted from 
HOPE-fixed specimens up to 5 years after fixation (22).  High-quality DNA suitable 
for use in array-CGH profiling experiments can successfully be extracted from tissues 
fixed using this method (supplementary figures 1 and 2).  The HOPE technique, 
although marginally more time-consuming may therefore be important in enabling 
clinical diagnosis, while allowing for fundamental retrospective research studies. 
Deleted:  
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To conclude, we suggest that the use of suitable high-quality DNA will improve our 
confidence in identifying key genetic alterations in disease states such as cancer. 
Advances in DNA extraction methods and array-CGH protocols may increase the 
reliability of DNA profiles acquired from FFPE material, and implementation of new, 
multi-purpose fixatives may further improve the quality and suitability of DNA 
extracted from fixed tissue specimen while maintaining morphology for diagnosis. 
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Figure 2 
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Figure 3 
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Figure Legends 
Figure 1.  Assessment of genomic DNA integrity via agarose gel electrophoresis. 
Genomic DNA (100ng) extracted from cell lines and clinical tissue, with varying 
degrees of degradation is shown.  High molecular weight (HMW) and low molecular 
weight (LMW) DNA are indicated. 100bp or 1kb DNA ladders from Promega were 
used as DNA size markers (M). 
a. Lanes 1-3: DNA extracted from FFPE clinical tissues.  Lanes 4-6: DNA extracted 
from fresh-frozen clinical tissues.  Lane 7: DNA extracted from FFPE T47D cell line 
sample.  Lane 8: DNA extracted from fresh T47D cell line sample.  Lane 9: DNA 
extracted from snap-frozen O.C.T.-embedded T47D cell line sample.  
 
Figure 2.  Numbers of genetic changes detected in DNA from matched FFPE and 
fresh or fresh-frozen samples using array-CGH. 
a. Total number of statistically relevant genetic changes detected in matched T47D 
cell line samples and matched clinical samples.   
b. Number of DNA amplifications versus deletions detected in matched T47D cell 
line samples and matched clinical samples. 
 
 
Figure 3. Array-CGH profiles of fresh-frozen and FFPE tissue DNA. 
a.  Array-CGH spectral profiles of differentially-processed T47D cancer cell pellets. 
1. Fresh T47D cell line DNA. 2.  Snap-frozen O.C.T. embedded T47D cell line DNA. 
3. FFPE T47D cell line DNA.   
b. Array-CGH spectral profiles of matched fresh-frozen and FFPE DNA extracted 
from colon cancer clinical samples. 4. Tissue 1 fresh-frozen DNA. 5. Tissue 1 FFPE 
DNA. 6. Tissue 2 fresh-frozen DNA. 7. Tissue 2 FFPE DNA. 8. Tissue 3 fresh-frozen 
DNA. 9. Tissue 3 FFPE DNA. 
Green: Statistically-significant genetic amplifications, Red: Statistically-significant 
genetic deletions. 
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Supplementary Figures 
Supplementary Figure 1 
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Supplementary Figure 2 
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Supplementary Figure Legends 
 
 
Supplementary Figure 1. Assessment of genomic DNA integrity via agarose gel 
electrophoresis 
Lane 1: DNA extracted from fresh T47D pellet. Lane 2: DNA extracted from snap-
frozen O.C.T.-embedded T47D cell line sample. Lane 3: DNA extracted from T47D 
pellet fixed for 1hr in 10% NBF. Lane 4: DNA extracted from T47D pellet fixed for 
24hr in 10% NBF. Lane 5: DNA extracted from HOPE-fixed T47D pellet. 
 
 
Supplementary Figure 2. Array-CGH profiles of DNA non-embedded 
differentially fixed T47D pellets. 
1. Fresh T47D cell line DNA for comparison. 2. DNA extracted from HOPE-fixed 
T47D cell pellet. 3. DNA extracted from 1hr 10%NBF-fixed T47D cell pellet. 4. 
DNA extracted from 24hr 10%NBF-fixed T47D cell pellet. 
Green: Statistically-significant genetic amplifications, Red: Statistically-significant 
genetic deletions. 
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